Stay updated on Fulvestrant & Pyrotinib in HR+/HER2+ Clinical Trial
Sign up to get notified when there's something new on the Fulvestrant & Pyrotinib in HR+/HER2+ Clinical Trial page.

Latest updates to the Fulvestrant & Pyrotinib in HR+/HER2+ Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.3%
- Check20 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, and API users can provide input before this change. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference6%
- Check27 days agoNo Change Detected
- Check48 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.3%
- Check62 days agoChange DetectedThe page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.SummaryDifference1.0%
- Check70 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.3%
- Check113 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
Stay in the know with updates to Fulvestrant & Pyrotinib in HR+/HER2+ Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fulvestrant & Pyrotinib in HR+/HER2+ Clinical Trial page.